{"id":"NCT01095666","sponsor":"AstraZeneca","briefTitle":"A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2010-03-30","resultsPosted":"2017-09-11","lastUpdate":"2017-09-11"},"enrollment":1484,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["BMS-512148"]},{"type":"DRUG","name":"Dapagliflozin","otherNames":["BMS-512148"]},{"type":"DRUG","name":"Metformin","otherNames":["GlucophageÂ®"]},{"type":"DRUG","name":"Dapagliflozin Placebo","otherNames":[]},{"type":"DRUG","name":"Pioglitazone","otherNames":[]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"EXPERIMENTAL"},{"label":"Group 3","type":"EXPERIMENTAL"}],"summary":"The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in Asian patients with Type 2 Diabetes who are not well controlled on metformin alone. The safety of this treatment will also be studied.","primaryOutcome":{"measure":"Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Placebo + Metformin","deltaMin":-0.23,"sd":0.0622},{"arm":"Dapagliflozin 5 mg + Metformin","deltaMin":-0.82,"sd":0.0607},{"arm":"Dapagliflozin 10 mg + Metformin","deltaMin":-0.85,"sd":0.0601}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":33,"countries":["China","India","South Korea"]},"refs":{"pmids":[],"seeAlso":["https://www.ncbi.nlm.nih.gov/pubmed/26589253"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":145},"commonTop":["HYPERLIPIDAEMIA","URINARY TRACT INFECTION","UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS","HYPERURICAEMIA"]}}